This CME-accredited activity, Multiple Myeloma, is designed to improve the care of Multiple patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of myeloma.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 7/1/2025 | 12/31/2025 |
Faculty
Shashank Cingam (MD )
Dr. Shashank Cingam is currently the Director of Blood & Marrow Transplantation/Cell Therapy at LSU Shreveport. Dr. Cingam joined LSU Shreveport from University of New Mexico Comprehensive Cancer Center (UNMCCC), where he was an assistant professor in the Division of Hematology/Oncology. He is a clinician and clinical investigator with a specialized focus on cellular therapies and hematopoietic stem cell transplantation for hematological disorders. Dr. Cingam earned his medical degree in India, followed by an internal medicine residency at Louisiana State University. He then completed a fellowship in hematology-oncology at UNMCCC and pursued an advanced fellowship in transplant/cell therapy at Stanford University. He is board certified in Internal Medicine, Hematology and Medical Oncology. His primary clinical interests include the diagnosis and treatment of multiple myeloma and aggressive B-Cell lymphomas, with a particular emphasis on cellular therapies.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Janssen Pharmaceuticals Relationship end date: 01/25/2024 Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Pfizer Relationship end date: 12/01/2024
- Medical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
- Hematologists
Target Audience
- Discuss new risk stratification for patients with Multiple Myeloma.
- Discuss indications and side effects of various treatment options.
- Discuss the effective management of side effects of cell and immunotherapies.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: